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In recent years, a huge progress in the field of radiotherapy could be observed. From treating
patients with kilo-voltage X-rays units to cutting edge technology that can deliver a certain
dose  with an extreme precision. Modern radiotherapy is characterized, among others, by an
individualized approach to the patient. This can be provided by functional imaging which is
another step toward a better tumor control. In this paper, we discuss the potential applica-




on  dose painting. Some limitations of this approach will also be evaluated.
©  2017 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
researchers. There are still some aspects that need to beET
.  Introduction
he year 1895, when Wilhelm Röntgen discovered X-rays, may
e assumed as the beginning of radiotherapy. Shortly after this
reat discovery, first patients were treated. Early applications
ere done for skin cancers, although neither biological nor
hysical properties of ionizing radiation were understood.1,2
ince then, new developments were implemented to improve
he quality and precision of radiation delivery.3–5 One of
hem was the invention of new imaging techniques e.g.
ositron Emission Tomography (PET) or Magnetic Resonance
maging (MRI). Combining modern diagnostic imaging with
 cutting edge radiotherapy technology may bring further
mprovement.
Such a combination was first suggested by Ling et al.6
ho  proposed the concept of integrating physical (which is
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507-1367/© 2017 Greater Poland Cancer Centre. Published by Elsevier Sthe state of art nowadays) and biological conformality in
radiotherapy. The main idea was to use functional images
that may provide additional information on metabolism,
physiology or genotype, in the treatment planning process.
Knowing the tissue differentiation and biology inside the
tumor, the dose distribution could be tailored accordingly.
It is well known that hypoxic regions are resistant to treat-
ment and that reduces the chance for recovery.7 Hence,
escalating the treatment dose in that area could increase
the local control. Such individual approach to both anatomy
and biology of the patient’s tumor is called dose painting
(DP).
DP is now being thoroughly investigated by many
8–11nd Cancer Centre, Garbary 15, 61-866 Poznan, Poland.
solved before implementing this method into clinical prac-
tice. Moreover, clinical studies should be carried out in order
to prove the therapeutic gain of DP.
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In this article, the summary of the functional imaging
in radiotherapy treatment planning will be reviewed with
emphasis on the dose painting method. Furthermore, poten-
tial limitations and uncertainties are discussed.
1.1.  Dose  painting  by  contours  vs.  numbers
Based on functional images, one may determine the
functional gross tumor volume (fGTV) which may be homoge-
nously escalated to a higher than typical therapeutic dose. The
level of dose prescription in this region is equal for all voxels
in the fGTV region.6 This is called Dose Painting by Contours
(DPBC). A more  sophisticated method of dose painting is when
the dose inside fGTV is prescribed according to the intensity
of the functional image  signal. This is called Doe Painting by
Numbers (DPBN).12 For example, after PET imaging the fGTV
was contoured. For DPBC situation, a dose will be increased for
all voxels in this region by “X” Gy. However, for DPBN the pre-
scription dose inside fGTV will vary according to the amount
of radiopharmaceutical accumulation. The dose increase in
the voxels is correlated with the increase of the PET signal.
The concept of dose painting was introduced by Ling and
colleagues6 in 2000. One year later, these theoretical consid-
erations were realized by Chao et al.,13 who showed that dose
may be increased up to 80 Gy in the hypoxic region located
in the head and neck area. Idea of DPBC is clinically feasi-
ble and treatment planning is not complicated. Moreover, it
can be easily performed using a typical commercial treatment
planning software. The drawback of DPBC is that higher boost
levels cannot be obtained using this method due to toxicity.14
In 2005, Bentzen proposed a new aspect of dose paint-
ing by the introduction of DPBN.12 With this method, higher
dose escalation may be obtained. However, this method is far
more complex and sometimes special software is required.
DPBN planning has previously been proven feasible using vol-
umetric modulated arc therapy,15 tomotherapy11,16 and proton
therapy.17
1.2.  Functional  imaging
Structural imaging (e.g. Computed Tomography (CT) or MRI)
creates visual representations of patient’s interior. Whereas,
functional imaging detects or measures changes occurring
inside a certain tissue or organ. Nowadays, CT is a gold stan-
dard imaging technique in radiotherapy. However, functional
imaging may be a helpful tool in determining tumor volume,
efficacy of the treatment or staging.
The most common molecular images used for tumor
volume delineation and assessment of pathophysiological
characteristics of tissue are PET data. Depending on the tracer
used, different information is visualized. The most popular
and understood tracer is fluorine-18 fludeoxyglucose (FDG)
that provides metabolic and functional information useful
during the radiotherapy process. It was already used in some
clinical trials where dose escalation was based on FDG avid
area inside the tumor volume.18–20A lot of research was done also with other PET tracers.
Particularly, with those that visualize tumor hypoxia which
was associated with treatment failure. It is well documented
that hypoxic microenvironment makes cancer cells moreiotherapy 2 2 ( 2 0 1 7 ) 327–330
aggressive and resistant to treatment.21 For this reason,
patients with hypoxic regions could potentially benefit from
escalating the radiation dose in those regions. However, quan-
tification of tumor hypoxia based on PET still needs to be
standardized. There have been several studies that used surro-
gates for hypoxia but most of them used different approach for
thresholding – from visual, standardized uptake value (SUV)
to kinetic analysis.22–24
Another important aspect is the selection of the appro-
priate PET tracer. There are several hypoxia tracers, e.g.
18F-fluoromisonidazole (18F-FMISO), 18F-fluoroazomycin-
arabinoside (18F-FAZA) or copper(II)-diacetyl-bis(N(4)-
methylthiosemicarbazone) (Cu-ATSM). However, all of
them have different characteristics and there is no particular
hypoxia tracer that is superior to others.25
For many  types of tumors, proliferation of cancer cells was
also linked to treatment failure. Thus, a PET tracer that is a
proliferation marker, e.g. 18F-fluorothymidine (FLT), may be
used for dose painting26 or radiotherapy adaptation.
Only a few studies have been found in the literature
regarding dose painting based on MR images. In some of
them, dynamic contrast enhanced magnetic resonance imag-
ing (DCE-MRI) was employed. This is another method used for
estimation of tumor oxygenation27 and it was shown that it
may be a good estimator of local control for some tumors.28
Søvik et al.29 and Chen et al.30 have used this imaging modal-
ity for escalation of therapeutic dose with DPBN in head
and neck and brain tumors, respectively. However, acquisition
and interpretation of DCE-MRI data should be made carefully
because it is very challenging.31
Diffusion-weighted MRI (DW-MRI) is another technique
that may be applied in the personalized radiotherapy treat-
ment planning. DW-MRI is used as an estimate of tumor cell
density.31 Dirix et al.32 showed a potential role of this method
for dose painting in the head and neck region. Moreover, Thor-
warth et al.33 showed that combining DW-MRI with other
functional images may be helpful during tailored radiotherapy
planning.
There were also studies based on magnetic resonance
spectroscopic imaging (MRS) which can identify regions of
abnormal metabolic activity.34 van Lin et al.35 showed that
DPBC escalation up to 90 Gy in prostate cancer patients is
feasible. The authors have used both DCE-MRI and MRS  for
determination of the boost area. Whereas, Deviers et al.36
showed that MRS  may be a future tool to define additional
biological target volumes for DP in patients with glioblastoma
multiforme.
1.3.  Limitations  and  uncertainties
Personalized radiotherapy treatment planning based on func-
tional imaging requires some features during the whole chain
of radiotherapy preparation to be maintained. First of all, the
patient must be positioned the same way during imaging and
treatment, which may be sometimes cumbersome, e.g. dedi-
cated coils for MR  imaging. As a result, the table top should
be flat and the ability to mount fixations e.g. thermoplastic
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When it comes to fGTV delineation, some compromise
ust be adopted. The main limitation would be the voxel size
f functional imaging which for PET is 3–5 mm.  This value
eems to be enormous when biological effects are considered,
.g. hypoxia cells can be observed in a micrometer scale. Due
o this fact, some hypoxic cells may not be detected and, as
 result, not included in the treatment planning. Moreover, in
ne voxel several biological processes may take place so the
ignal will be averaged.37 Another limitation would be the
mage noise which is present in all types of functional imag-
ng due to reconstruction algorithms. These imperfections
f functional imaging may have an impact on DPBN where
ach voxel is attributed to different dose level and, hence,
he above mentioned limitations may play a significant role.
owever, this aspect is controversial and probably clinical
rials will help solve it.
Another aspect that is raised by the radiotherapy commu-
ity is that the dependence of signal intensity of functional
maging and therapeutic dose is unknown. Until now, a
ast majority of papers concerning DPBN assumed a linear
elationship.8–11,15,16 However, this assumption is theoretical
nd no evidence of this hypothesis has been proven in the
iterature.
In the case of treatment plan evaluation, the typical
ethodology is insufficient. In standard treatment planning
he goal is to achieve a homogenous and conformal dose
o the target volume and at the same time spare organs at
isk. However, in DPBN, the dose in fGTV is not homogenous
 it is intentionally heterogeneous. Hence, new methods of
lan evaluation have been proposed in the literature. One of
hem is the new parameter – quality factor and quality-volume
istogram proposed by Vanderstraeten et al.10 Park et al. intro-
uced the index of achievement and the index of hotness and
oldness.38
Geometrical uncertainties is another limitation of DPBN.
ince the dose distribution is very sophisticated, it is vulner-
ble to patient positioning as proven by Korreman et al.15
owever, lately, Sterpin et al.39 and Witte et al.40 have pro-
osed some solutions of that problem.
Even though there are some concerns regarding DP, some
linical trials are now in progress, e.g. in Ghent, Belgium,8,9,20
openhagen, Denmark,41 and Amsterdam, the Netherlands.19
ll of them refer to the head and neck cancer and are based
n the FDG PET.
.  Conclusion
P based on functional imaging is an example of an individu-
lized approach to treatment that seems to be very promising.
owever, as discussed in this review, there are some concerns
egarding the usage of functional imaging in DP radiother-
py treatment planning. Much  research still needs to be done
nd, hopefully, ongoing clinical trials will provide some new
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